Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-02-22
2005-02-22
Qazi, Sabiha N. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
C552S653000
Reexamination Certificate
active
06858595
ABSTRACT:
Methods of treating inflammatory bowel disease are described, and in particular the prevention and treatment of inflammatory bowel disease in humans as well as other animals. These methods involve the administration of biologically active vitamin D compounds, and therapeutic compositions thereof, so that the symptoms of Inflammatory Bowel Disease are reduced or relieved.
REFERENCES:
patent: 4312806 (1982-01-01), Lambert et al.
patent: 4638043 (1987-01-01), Szycher et al.
patent: 5216002 (1993-06-01), Gidda et al.
patent: 5238931 (1993-08-01), Yoshikawa et al.
patent: 5294630 (1994-03-01), Blake et al.
patent: 5368854 (1994-11-01), Rennick
patent: 5391555 (1995-02-01), Marshall et al.
patent: 5446035 (1995-08-01), Neef et al.
patent: 5506213 (1996-04-01), Carson et al.
patent: 5518725 (1996-05-01), Daynes et al.
patent: 5552439 (1996-09-01), Panetta
patent: 5569680 (1996-10-01), Wu
patent: 5583125 (1996-12-01), Steinmeyer et al.
patent: 5643602 (1997-07-01), Ulmius
patent: 5663157 (1997-09-01), Steinmeyer et al.
patent: 5710142 (1998-01-01), Calverley et al.
patent: 5711964 (1998-01-01), Dattagupta et al.
patent: 5716945 (1998-02-01), Grue-Sorensen
patent: 5716946 (1998-02-01), De Luca et al.
patent: 5756449 (1998-05-01), Andersen et al.
patent: 5756733 (1998-05-01), Hesse et al.
patent: 5786347 (1998-07-01), Hesse et al.
patent: 5792795 (1998-08-01), Buser et al.
patent: 5811562 (1998-09-01), Hesse et al.
patent: 5824313 (1998-10-01), Daynes et al.
patent: 5830505 (1998-11-01), Fischer et al.
patent: 5834016 (1998-11-01), Naeff et al.
patent: 5834021 (1998-11-01), Speirs
patent: 5851548 (1998-12-01), Dattagupta et al.
patent: 5872140 (1999-02-01), Hesse et al.
patent: 5876746 (1999-03-01), Jona et al.
patent: 5877168 (1999-03-01), Miyamoto et al.
patent: 5883271 (1999-03-01), Ono
patent: 5888969 (1999-03-01), Girten et al.
patent: 5889028 (1999-03-01), Sandborn et al.
patent: 5891865 (1999-04-01), De Luca et al.
patent: 5902806 (1999-05-01), Ikeda et al.
patent: 5905074 (1999-05-01), Schneider
patent: 5929056 (1999-07-01), Mourino et al.
patent: 5932214 (1999-08-01), Lobb et al.
patent: 5932565 (1999-08-01), Grue-Sorensen
patent: 5936105 (1999-08-01), Paaren
patent: 5952317 (1999-09-01), De Luca et al.
patent: 5981597 (1999-11-01), Wu
patent: 6214373 (2001-04-01), Snowden
patent: 6440953 (2002-08-01), DeLuca et al.
patent: 20030188756 (2003-10-01), Cantoma
patent: 44 05 545 (1995-08-01), None
patent: 0927721 (1997-12-01), None
patent: WO 9630326 (1996-10-01), None
patent: WO 9851644 (1998-11-01), None
patent: WO 9851678 (1998-11-01), None
patent: WO 0142205 (2001-06-01), None
Tada, M. et al. (DN BA81:48751, BIOSIS, abstract of J. Jpn Soc. Colo-Proctol, (1985), 38 (6), 663-668).*
Barrat et al. (DN 136:339213, CAPLUS, abstract of J. of Experimental Medicine (2002), 195(5), 603-616).
Penna et al. (DN 132:292680, CAPLUS, abstract of J. of Immunology (2000), 164(5), 2405-2411).
Darn et al. (DN 132:146376, CAPLUS, abstract of J. of Investigative Dermatology (1999), 113(6), 1082-1089).
Bemiss, C. J. et al., “Interleukin-2 is one of the targets of 1,25-dihydroxyvitamin D3 in the immune system,”Archives of Biochemistry and Biophysics,402 (2002), pp. 249-254; published by Elsevier Science (USA).
Bickston, S.J. et al., “Recombinant Interleukin 10 for the Treatment of Active Crohn's Disease: Lessons in Biologic Therapy,”Gastroenterology,119 (6) (2000), pp. 1781-1783; published by American Gastroenterological Association (USA).
Cantorna, M. T. et al., “1,25-Dihydroxycholecalciferol Prevents and Ameliorates Symptoms of Experimental Murine inflammatory Bowel Disease,”J. Nutr.,130 (2000), pp. 2648-2652; published by American Society for Nutritional Sciences (USA).
Colombel, J-F. et al., “Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease,”Gut,49 (2001) pp. 42-46; published by British Medical Association (United Kingdom).
Cornillie, F. et al., “Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease,”Aliment Pharmacol Ther.,15 (2001), pp. 463-473; published by Blackwell Science Ltd.
Fedorak, R. N. et al., “Recombinant Human Interleukin 10 in the Treatment of Patients with Mild to Moderately Active Crohn's Disease,”Gastroenterology,119 (2000), pp. 1473-1482; published by American Gastroenterological Association (USA).
Fedorak, R. N. et al., “Human Recombinant Interleukin-10 is Safe and Well Tolerated But Does Not Induce Remission in Steroid Dependent Crohn's Disease,”Gastroenterology,120 (Supp. 1) (2001), p. A-127; published by W.B. Saunders (Philadelphia, USA).
Hanauer, S. B. et al., “Evolving Treatment Strategies for Inflammatory Bowel Disease,”Annu. Rev. Med.,52 (2001), pp. 299-318; published by Annual Reviews.
Kam, L. Y. et al., “TNF-α antagonists for the treatment of Crohn's disease,”Exp. Opin. Pharmacother.,1 (4) (2000), pp. 615-622; published by Ashley Publications Ltd.
Puchner, Thomas C. et al., “Successful Desensitization and Therapeutic Use of Infliximab in Adult and Pediatric Crohn's Disease Patients with Prior Anaphylactic Reaction,”Inflamm. Bowel Dis.,7 (1) (2001), pp. 34-37; published by Crohn's & Colitis Foundation of America, Inc. (USA).
Ricart, E. et al., “Infliximab for Crohn's Disease in Clinical Practice at the Mayo Clinic: The First 100 Patients,”Am. J. of Gastroenterology,96 (3) (2001), pp. 722-729; published by Am. Coll. of Gasstroenterology (USA).
Sandborn, W. J. et al., “An Engineered Human Antibody to TNF (CDP571) for Active Crohn's Disease: A Randomized Double-Blind Placebo-Controlled Trial,”Gastroenterology,120 (2001), pp. 1330-1338; published by American Gastroenterological Association (USA).
Sandborn, W. J. et al., “Etanercept for Active Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial,”Gastroenterology,121 (5) (2001), pp. 1088-1094; published by American Gastroenterological Association (USA).
Sands, B. E. et al., “Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study,”Inflamm. Bowel Dis.,7 (2) (2001), pp. 83-88; published by Crohn's & Colitis Foundation of America, Inc. (USA).
Schreiber, S. et al., “Safety and Efficacy of Recombinant Human Interleukin 10 in Chronic Active Crohn's Disease,”Gastroenterology,119 (6) (2000), pp. 1461-1472; published by American Gastroenterological Association (USA).
Schreiber, S. et al., “Immunoregulatory Role of Interleukin 10 in Patients With Inflammatory Bowel Disease,”Gastroenterology,108 (5) (1995), pp. 1434-1444; published by American Gastroenterological Association (USA).
Stio, M. et al., “Suppressive effect of 1,25-dihydroxyvitamin D3and its analogues EB 1089 and KH 1060 on T lymphocyte proliferation in active ulcerative colitis,”Biochemical Pharmacology,61 (2001), pp. 365-371; published by Elsevier Science Inc.
Targan, S. R., “Biology of inflammation in Crohn's disease: Mechanisms of action of anti-TNF-α therapy,”Can. J. Gastroenterology,14 (Suppl. C) (2000), pp. 13C-16C.
van Berge Henegouwen, G. P., [“Consensus for infliximab treatment of patients with Crohn's disease”],Ned Tijdschr. Geneeskd.,144 (38) (2000), pp. 1844-1845 (Netherlands). English Abstract is provided on p. 1845 of the reference.
van Deventer, S. J. et al., “Multiple Doses of Intravenous Interleukin 10 in Steroid-Refractory Crohn's Disease,”Gastroenterology,113 (2) (1997), pp. 383-389; published by American Gastroenterological Association (USA).
Harries, A.D. et al., “Vitamin D status in Crohn's disease: association with nutrition and disease activity,”Gut,26 (1985), pp. 1197-1203.
Issenman, R. M., “Bone Mineral Metabolism in Pediatric Inflammatory Bowel Disease,”Inflamm. Bowel Dis.,5 (3) (1999), pp. 192-199; published by Crohn's & Colitis Fou
Hayes Colleen E.
Nashold Faye E.
Foley & Lardner LLP
Qazi Sabiha N.
Wisconsin Alumni Research Association
LandOfFree
Use of biologically active vitamin D compounds for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of biologically active vitamin D compounds for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of biologically active vitamin D compounds for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3479004